Table 1.

Baseline tumor assessments: correlation with response to single-agent pembrolizumab

	PMR∗, N = 11†,‡	Near-CMR§, N = 8†	CMR‖, N = 11†	P value¶
Stage				.6
Early	5 (45)	4 (50)	3 (27)
Advanced	6 (55)	4 (50)	8 (73)
Epstein-Barr virus–encoded small RNAs				.3
Negative	7 (88)	5 (83)	4 (50)
Positive	1 (12)	1 (17)	4 (50)
Missing	3	2	3
9p24.1 Alterations				.4
Polysomy or copy gain	4 (36)	5 (71)	5 (50)
Amplification by ratio#	7 (64)	2 (29)	5 (50)
Missing	0	1	1
Percent of residual disomic HRS cells	0.0 (0.0-0.4)	0.1 (0.0-0.9)	0.0 (0.0-0.5)	.4
Missing	0	1	1
Percent of HRS cells with polysomy or CNG	0.8 (0.2-1.0)	0.9 (0.1-1.0)	0.9 (0.5-1.0)	.9
Missing	0	1	1
Percent of HRS cells with amplification by ratio∗, #	0.0 (0.0-0.8)	0.0 (0.0-0.1)	0.0 (0.0-0.3)	.3
Missing	0	1	1
PD-L1 H score	213.0 (122.0-300.0)	211.5 (20.0-300.0)	221.5 (62.0-300.0)	>.9
Missing	0	0	1
PD-L1 H score terciles				>.9
0, 190	3 (27)	3 (38)	2 (20)
190, 240	4 (36)	2 (25)	4 (40)
240, 300	4 (36)	3 (38)	4 (40)
Missing	0	0	1
PD-L2 H score	20.0 (0.0-135.0)	30.0 (0.0-180.0)	15.0 (0.0-60.0)	.4
Missing	0	0	1
PD-L2 H score terciles				.4
0, 10	1 (9.1)	3 (38)	4 (40)
10, 50	5 (45)	1 (12)	2 (20)
50, 200	5 (45)	4 (50)	4 (40)
Missing	0	0	1
STAT3 H score	300.0 (140.0-300.0)	300.0 (60.0-300.0)	250.0 (70.0-300.0)	.5
Missing	0	0	1

^∗PMR is defined as >50% but <90% reduction in MTV.

^†n (%) or median (minimum-maximum).

^‡Includes 1 patient with an indeterminate response according to the Lymphoma Response to Immunomodulatory Therapy Criteria.

^§Near-CMR defined as ≥90% reduction in MTV, but less than CMR by Lugano 2014 criteria.

^‖CMR per Lugano 2014 criteria.

^¶Fisher exact test and Kruskal-Wallis rank-sum test.

^#Amplification defined as a target to probe ratio > 3:1.